Structure of the G60A mutant of Ras: implications for the dominant negative effect
- PMID: 15878843
- DOI: 10.1074/jbc.M502240200
Structure of the G60A mutant of Ras: implications for the dominant negative effect
Abstract
Substituting alanine for glycine at position 60 in v-H-Ras generated a dominant negative mutant that completely abolished the ability of v-H-Ras to transform NIH 3T3 cells and to induce germinal vesicle breakdown in Xenopus oocytes. The crystal structure of the GppNp-bound form of RasG60A unexpectedly shows that the switch regions adopt an open conformation reminiscent of the structure of the nucleotide-free form of Ras in complex with Sos. Critical residues that normally stabilize the guanine nucleotide and the Mg(2+) ion have moved considerably. Sos binds to RasG60A but is unable to catalyze nucleotide exchange. Our data suggest that the dominant negative effect observed for RasG60A.GTP could result from the sequestering of Sos in a non-productive Ras-GTP-guanine nucleotide exchange factor ternary complex.
Similar articles
-
Mutagenesis of the H-ras p21 at glycine-60 residue disrupts GTP-induced conformational change.Biochemistry. 1995 Mar 14;34(10):3470-7. doi: 10.1021/bi00010a040. Biochemistry. 1995. PMID: 7880841
-
Characterization of a Ras mutant with identical GDP- and GTP-bound structures.Biochemistry. 2009 Dec 8;48(48):11449-57. doi: 10.1021/bi901479b. Biochemistry. 2009. PMID: 19883123 Free PMC article.
-
Structure-based mutagenesis reveals distinct functions for Ras switch 1 and switch 2 in Sos-catalyzed guanine nucleotide exchange.J Biol Chem. 2001 Jul 20;276(29):27629-37. doi: 10.1074/jbc.M101727200. Epub 2001 May 1. J Biol Chem. 2001. PMID: 11333268
-
How does the switch II region of G-domains work?FEBS Lett. 1993 Mar 29;320(1):1-6. doi: 10.1016/0014-5793(93)81644-f. FEBS Lett. 1993. PMID: 8462668 Review.
-
Signal activation and inactivation by the Gα helical domain: a long-neglected partner in G protein signaling.Sci Signal. 2012 May 29;5(226):re2. doi: 10.1126/scisignal.2003013. Sci Signal. 2012. PMID: 22649098 Free PMC article. Review.
Cited by
-
Discovery of Small Molecule NSC290956 as a Therapeutic Agent for KRas Mutant Non-Small-Cell Lung Cancer.Front Pharmacol. 2022 Jan 5;12:797821. doi: 10.3389/fphar.2021.797821. eCollection 2021. Front Pharmacol. 2022. PMID: 35069209 Free PMC article.
-
Spiclomazine displays a preferential anti-tumor activity in mutant KRas-driven pancreatic cancer.Oncotarget. 2018 Jan 8;9(6):6938-6951. doi: 10.18632/oncotarget.24025. eCollection 2018 Jan 23. Oncotarget. 2018. PMID: 29467941 Free PMC article.
-
An attenuated phenotype of Costello syndrome in three unrelated individuals with a HRAS c.179G>A (p.Gly60Asp) mutation correlates with uncommon functional consequences.Am J Med Genet A. 2015 Sep;167A(9):2085-97. doi: 10.1002/ajmg.a.37128. Epub 2015 Apr 25. Am J Med Genet A. 2015. PMID: 25914166 Free PMC article.
-
Structure of the dominant negative S17N mutant of Ras.Biochemistry. 2010 Mar 9;49(9):1970-4. doi: 10.1021/bi9020742. Biochemistry. 2010. PMID: 20131908 Free PMC article.
-
Monitoring Ras Interactions with the Nucleotide Exchange Factor Son of Sevenless (Sos) Using Site-specific NMR Reporter Signals and Intrinsic Fluorescence.J Biol Chem. 2016 Jan 22;291(4):1703-1718. doi: 10.1074/jbc.M115.691238. Epub 2015 Nov 12. J Biol Chem. 2016. PMID: 26565026 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
- Actions
- Actions
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
